Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal

26/10/2015 - 2 minutes

CRIPSR’s hype is not going down yet.

CRIPSR/Cas9 or Cpf1 is a revolutionising gene editing tool, which almost won the Nobel Prize of this year (it won nearly all the other biology prizes already).

It also caught great interest from the industry and venture capitalists. The leading Biotechs includes:

Now CRISPR Therapeutics has just signed a massive €2.29Bn Deal.

It was signed with Boston-based Vertex Pharmaceuticals. This 2000+ employee company is the third biggest Biotech in Boston after Genzyme (now part of Sanofi) and Biogen.

The goal of this collaboration is to develop treatments aimed at the underlying genetic causes of human disease. It will start on discovering treatments to address the mutations and genes known to cause and contribute to Cystic fibrosis (the special focus of Vertex) and Sickle Cell Anemia.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!